Privosegtor

Privosegtor
Clinical data
Other names	ACT-01; BN-201; G-79; OCS 05
Legal status
Legal status	investigational;
Identifiers
	IUPAC name N-[2-[(2-Amino-2-oxoethyl)-[3-(2-oxopyrrolidin-1-yl)propyl]amino]-2-oxoethyl]-2-[2-(2-fluorophenyl)ethylamino]-N-(2-methylpropyl)acetamide;
CAS Number	1361200-34-1;
PubChem CID	66610682;
IUPHAR/BPS	13222;
DrugBank	DB18295;
ChemSpider	64853740;
UNII	KCN37L7EIH;
ChEBI	CHEBI:759947;
ChEMBL	ChEMBL6068029;
Chemical and physical data
Formula	C25H38FN5O4
Molar mass	491.608 g·mol−1
3D model (JSmol)	Interactive image;
	SMILES CC(C)CN(CC(=O)N(CCCN1CCCC1=O)CC(=O)N)C(=O)CNCCC2=CC=CC=C2F;
	InChI InChI=1S/C25H38FN5O4/c1-19(2)16-31(24(34)15-28-11-10-20-7-3-4-8-21(20)26)18-25(35)30(17-22(27)32)14-6-13-29-12-5-9-23(29)33/h3-4,7-8,19,28H,5-6,9-18H2,1-2H3,(H2,27,32); Key:ODCKWAPNRBCXHV-UHFFFAOYSA-N;

Privosegtor is an investigational new drug that is being evaluated by Oculis Pharma for the treatment of optic neuritis.^[1] It is a serine/threonine-protein kinase SGK2 activator that is claimed to have neuroprotective properties.^[1]^[2]^[3]

Clinical trials

Privosegtor is currently in phase 3 clinical trials for optic neuritis.^[4]

1 2 "Privosegtor - Oculis Pharma". AdisInsight. Springer Nature Switzerland AG.
↑ Louapre C, Beigneux Y, Maestri F, Meyniel C, Touitou V (May 2026). "Remyelination and neuroprotection translational trials: Lessons from optic neuritis". Revue Neurologique. 182 (5). Paris: 478–487. doi:10.1016/j.neurol.2026.03.009. PMID 41966939.
↑ Novack GD (2026). "Eyes on New Product Development". Journal of Ocular Pharmacology and Therapeutics : The Official Journal of the Association for Ocular Pharmacology and Therapeutics. 42 (1): 5–6. doi:10.1177/10807683261427261. PMID 41761853.
↑ Clinical trial number NCT07623668 for "Privosegtor Investigation in Optic Neuropathies Efficacy Evaluation Research (PIONEER-1) " at ClinicalTrials.gov

This pharmacology-related article is a stub. You can help Wikipedia by adding missing information.